

ORAL PRESENTATION

Open Access

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)

J Eron¹, JM Livrozet², P Morlat³, A Lazzarin⁴, C Katlama⁵, T Hawkins⁶, T Fujiwara⁷, R Cuffe⁸, C Vavro⁹, J Santiago¹⁰, M Ait-Khaled⁸, S Min^{9*}, JM Yeo⁸

From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010

Background

S/GSK1349572(572) showed potent activity in Phase 2 studies in INI-naïve HIV-infected subjects and limited cross-resistance to raltegravir (RAL) and elvitegravir *in vitro*. VIKING is an ongoing 24-week Phase 2b pilot study assessing 572 in subjects with RAL-resistant HIV. A good antiviral response during the functional monotherapy phase (through Day 11) of this pilot study was observed with a strong correlation between baseline susceptibility to 572 and response.

Methods

27 RAL-experienced, adult subjects, with screening plasma HIV-1 RNA ≥ 1000 c/mL and genotypic resistance to RAL and ≥ 2 other ART classes, received 572 50mg QD in Cohort I while continuing their failing regimen (without RAL). At Day 11 the background regimen was optimised, where feasible, and 572 continued. The antiviral activity (primary end-point at Day 11), tolerability, safety and virology data through Week 24 of Cohort I are presented. A higher dose is being assessed.

Results

At Baseline, subjects harboured viruses displaying high level resistance to RAL (median fold change in susceptibility [FC] 161, range: 0.57- >166) and low median FC to 572 (1.46, range: 0.55-35). Median (IQR) Baseline CD4+ and plasma HIV-1 RNA were 110 cells/mm³ (40, 230) and 4.47 log₁₀c/mL (3.9, 4.9), respectively. Median

number (range) of prior ART drugs was 18 (10, 23). Twenty one (78%) subjects achieved plasma HIV-1 RNA <400 c/mL (n=11) or ≥ 0.7 log₁₀ c/mL decline (n=10) at Day 11 (primary end-point). Post Day 11, the optimised background regimen (OBR) phenotypic susceptibility score (PSS) was 0, 1 and ≥ 2 for 12 (44%), 7 (26%) and 8 (30%) subjects, respectively. 17 subjects continued therapy through Week 24 when 14/27 (52%) and 11/27 (41%) subjects achieved < 400 c/mL and < 50 c/mL, respectively by TLOVR. Response correlated with OBR PSS: 2/12 (17%) subjects with PSS =0, 4/7 (57%) with PSS=1 and 8/8 (100%) with PSS ≥ 2 achieved <400 c/mL at Week 24. Drug related AEs (any grade) were observed in 6 (22%) subjects. Two subjects with advanced AIDS died after withdrawal from study for SAEs (brain mass, non-Hodgkin's lymphoma with febrile bone marrow aplasia) unrelated to 572.

Conclusions

Despite high level baseline resistance to RAL and the limited activity of the OBR co-administered with 572, the majority of subjects achieved < 400 c/mL at Week 24 with improved response rates in those receiving at least one active background ART. S/GSK1349572 was generally well tolerated in this advanced population.

Author details

¹UNC School of Medicine, Center for AIDS Research Clinical Care, NC, USA. ²Hopital Edouard Herriot, Lyon, France. ³Service de médecine interne et maladies infectieuses, Hôpital Saint André (CHU), Bordeaux, France. ⁴San Raffaele Scientific Institute, Milan, Italy. ⁵Hopital de la Pitie-Salpetriere, Paris, France. ⁶Southwest CARE Center, Santa Fe, USA. ⁷Shionogi & Co. Ltd., Osaka,

⁹GlaxoSmithKline, Research Triangle Park, USA
Full list of author information is available at the end of the article

Japan. ⁸GlaxoSmithKline, Uxbridge, UK. ⁹GlaxoSmithKline, Research Triangle Park, USA. ¹⁰GlaxoSmithKline, Mississauga, Canada.

Published: 8 November 2010

doi:10.1186/1758-2652-13-S4-O51

Cite this article as: Eron *et al.*: Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961). *Journal of the International AIDS Society* 2010 **13**(Suppl 4):O51.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

